FABP1 and metabolic dysfunction-associated steatotic liver disease: In addition, the measurement of liver-type fatty acid-binding protein (FABP1/L-FABP), was also included as this protein is associated with dyslipidemia (elevated plasma triglycerides) and non-alcoholic fatty liver disease (NAFLD), a condition commonly seen in FHTG subjects [34].